These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7658878)

  • 1. Chemical brain anatomy in schizophrenia.
    Sedvall G; Farde L
    Lancet; 1995 Sep; 346(8977):743-9. PubMed ID: 7658878
    [No Abstract]   [Full Text] [Related]  

  • 2. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomography--examination of chemical transmission in the living human brain. Development of radioligands.
    Farde L; Hall H
    Arzneimittelforschung; 1992 Feb; 42(2A):260-4. PubMed ID: 1316756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 5. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Buchsbaum MS
    Neuropsychopharmacology; 1992 Aug; 7(1):67-8; discussion 73-5. PubMed ID: 1355970
    [No Abstract]   [Full Text] [Related]  

  • 6. PET scanning in schizophrenia, a critical evaluation. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Murphy D; Rapoport SI
    Neuropsychopharmacology; 1992 Aug; 7(1):59-61; discussion 73-5. PubMed ID: 1524656
    [No Abstract]   [Full Text] [Related]  

  • 7. Changes in cerebral dopamine metabolism and receptors during one-year neuroleptic administration and subsequent withdrawal: relevance to brain biochemistry in schizophrenia.
    Clow A; Jenner P; Theodorou A; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():53-5. PubMed ID: 6105799
    [No Abstract]   [Full Text] [Related]  

  • 8. [Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques].
    Szekeres G; Pávics L; Janka Z
    Ideggyogy Sz; 2002 Jul; 55(7-8):226-32. PubMed ID: 12201230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D2 receptors in schizophrenia studied in vivo.
    Crawley JC; Owens DG; Crow TJ; Poulter M; Johnstone EC; Smith T; Oldland SR; Veall N; Owen F; Zanelli GD
    Lancet; 1986 Jul; 2(8500):224-5. PubMed ID: 2873471
    [No Abstract]   [Full Text] [Related]  

  • 10. In vivo assessment of dopaminergic variables in schizophrenia.
    Martinot JL; Paillere-Martinot ML; Lecrubier Y; Dao-Castellana MH; Loc'h C; Poirier MF; Allilaire JF; Feline A; Manus A; Aubin F
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():470A-471A. PubMed ID: 1354053
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine receptor supersensitivity and schizophrenia: a review.
    Langer DH; Brown GL; Docherty JP
    Schizophr Bull; 1981; 7(2):208-24. PubMed ID: 7025187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine receptors, neuroleptics, and schizophrenia.
    Snyder SH
    Am J Psychiatry; 1981 Apr; 138(4):460-4. PubMed ID: 6111227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS; Moerlein SM
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins.
    Bai J; He F; Novikova SI; Undie AS; Dracheva S; Haroutunian V; Lidow MS
    Biol Psychiatry; 2004 Sep; 56(6):427-40. PubMed ID: 15364041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo neuropharmacology of schizophrenia.
    Bigliani V; Pilowsky LS
    Br J Psychiatry Suppl; 1999; (38):23-33. PubMed ID: 10884897
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia.
    Buchsbaum MS; Potkin SG; Marshall JF; Lottenberg S; Teng C; Heh CW; Tafalla R; Reynolds C; Abel L; Plon L
    Neuropsychopharmacology; 1992 May; 6(3):155-63. PubMed ID: 1599606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging dopamine transmission in schizophrenia. A review and meta-analysis.
    Laruelle M
    Q J Nucl Med; 1998 Sep; 42(3):211-21. PubMed ID: 9796369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol blocks the uptake of [18F]N-methylspiroperidol by extrastriatal dopamine receptors in schizophrenic patients.
    Yousef KA; Volkow ND; Schlyer DJ; Fowler JS; Wolf AP; Wang GJ; Smith MR; Brodie JD; Warner D
    Synapse; 1995 Jan; 19(1):14-7. PubMed ID: 7709339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The biochemistry of schizophrenia--a review.
    Shelley RK; Walsh N
    Ir Med J; 1985 May; 78(5):139-43. PubMed ID: 3891675
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.